(AOF) – Sensorion, a pioneering biotechnology company at the clinical stage, specializing in the development of new therapies to restore, treat and prevent hearing loss disorders, announces the extension for a period of five years of the framework agreement research partnership signed in 2019 with the Institut Pasteur. It grants Sensorion an exclusive license option to develop and commercialize gene therapy drug candidates from collaborative projects to address unmet medical needs in the field of hearing.
The agreement has been amended to be extended until December 31, 2028, to promote additional gene therapy development programs.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.